{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:58:44Z","timestamp":1790891924943,"version":"4.1.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:p>A number of oncogenic driver mutations have been identified in melanocytic nevi and melanoma, but translocations also play a role in tumorigenesis and provide potential therapeutic targets for malignant lesions. Various translocations, such as those involving the anaplastic lymphoma kinase (<jats:italic toggle=\"yes\">ALK<\/jats:italic>), neurotrophic tropomyosin receptor kinase 1 (<jats:italic toggle=\"yes\">NTRK1<\/jats:italic>), and <jats:italic toggle=\"yes\">NTRK3<\/jats:italic> have been reported in spitzoid melanocytic neoplasms leading to kinase-fusion proteins that result in immunohistochemically detectable ALK or NTRK expression. We have previously reported that ALK expression can be found in nonspitzoid primary and metastatic cutaneous melanomas. In this study we report that nonspitzoid metastasizing melanomas of adults may also harbor <jats:italic toggle=\"yes\">NTRK<\/jats:italic> fusions and that NTRK expression can be immunohistochemically detected in these tumors. Of 751 melanomas analyzed by next-generation sequencing, 4 metastatic melanomas were identified with <jats:italic toggle=\"yes\">NTRK<\/jats:italic> fusions, 3 involving <jats:italic toggle=\"yes\">NTRK1<\/jats:italic>, 1 involving <jats:italic toggle=\"yes\">NTRK2<\/jats:italic>. They occurred in 3 women and 1 man. Two of the corresponding primary tumors were from the trunk, 1 from an extremity and 1 tumor arose in anal skin. One primary tumor displayed features of superficial spreading melanoma and 3 were nodular melanomas. All tumors were cytologically characterized by the presence of large epithelioid melanocytes. All tumors were immunoreactive with anti-Trk antibody. Next-generation sequencing documented that the <jats:italic toggle=\"yes\">NTRK1<\/jats:italic> fusion partners included <jats:italic toggle=\"yes\">TRIM63<\/jats:italic>, <jats:italic toggle=\"yes\">DDR2<\/jats:italic>, and <jats:italic toggle=\"yes\">GON4L<\/jats:italic>. One tumor harbored an <jats:italic toggle=\"yes\">NTRK2-TRAF2<\/jats:italic> fusion. Thus, our findings document that <jats:italic toggle=\"yes\">NTRK<\/jats:italic> kinase fusions can occur in nonspitzoid metastasizing melanomas of adults. The presence of an <jats:italic toggle=\"yes\">NTRK<\/jats:italic> family fusion in these tumors may provide a therapeutic opportunity in a small subset of patients with metastatic melanoma.<\/jats:p>","DOI":"10.1097\/pas.0000000000001070","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T22:47:46Z","timestamp":1524264466000},"page":"1052-1058","source":"Crossref","is-referenced-by-count":89,"title":["Primary and Metastatic Melanoma With NTRK Fusions"],"prefix":"10.1097","volume":"42","author":[{"given":"Cecilia","family":"Lezcano","sequence":"first","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander N.","family":"Shoushtari","sequence":"additional","affiliation":[{"name":"Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Ariyan","sequence":"additional","affiliation":[{"name":"Surgery, Memorial Sloan Kettering Cancer, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis J.","family":"Hollmann","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus J.","family":"Busam","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"Jama"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1158\/1078-0432.CCR-14-0058","article-title":"Melanoma BRAF fusions\u2014letter","volume":"20","author":"Botton","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/pcmr.12148","article-title":"Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy","volume":"26","author":"Botton","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm.2166","article-title":"Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma","volume":"16","author":"Palanisamy","year":"2010","journal-title":"Nat Med"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1158\/1078-0432.CCR-15-1162","article-title":"Copy number changes are associated with response to treatment with carboplatin, paclitaxel, and sorafenib in melanoma","volume":"22","author":"Wilson","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/archderm.137.11.1507","article-title":"Genomic approaches to skin cancer diagnosis","volume":"137","author":"Bastian","year":"2001","journal-title":"Arch Dermatol"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1046\/j.1523-1747.1999.00787.x","article-title":"Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma","volume":"113","author":"Bastian","year":"1999","journal-title":"J Invest Dermatol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.yadr.2005.04.002","article-title":"Genomic analysis of melanocytic neoplasia","volume":"21","author":"Bauer","year":"2005","journal-title":"Adv Dermatol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1038\/ncomms4116","article-title":"Kinase fusions are frequent in Spitz tumours and spitzoid melanomas","volume":"5","author":"Wiesner","year":"2014","journal-title":"Nat Commun"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/PAS.0000000000000387","article-title":"Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions","volume":"39","author":"Yeh","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/PAS.0b013e3181c7d8b2","article-title":"Cutaneous clear cell sarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 12 cases emphasizing its distinction from dermal melanoma","volume":"34","author":"Hantschke","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/cup.12197","article-title":"Compound clear cell sarcoma misdiagnosed as a Spitz nevus","volume":"40","author":"Kiuru","year":"2013","journal-title":"J Cutan Pathol"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/1471-2407-11-380","article-title":"EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation","volume":"11","author":"Neumann","year":"2011","journal-title":"BMC Cancer"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nature15258","article-title":"Alternative transcription initiation leads to expression of a novel ALK isoform in cancer","volume":"526","author":"Wiesner","year":"2015","journal-title":"Nature"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0002-9440(10)64609-3","article-title":"Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features","volume":"157","author":"Bastian","year":"2000","journal-title":"Am J Pathol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/path.4775","article-title":"Activating MET kinase rearrangements in melanoma and Spitz tumours","volume":"240","author":"Yeh","year":"2016","journal-title":"AM J Pathol"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/path.4775","article-title":"NTRK3 kinase fusions in Spitz tumours","volume":"240","author":"Yeh","year":"2016","journal-title":"J Pathol"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/PAS.0000000000000611","article-title":"Primary and metastatic cutaneous melanomas express ALK through alternative transcriptional initiation","volume":"40","author":"Busam","year":"2016","journal-title":"Am J Surg Path"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"395","DOI":"10.6004\/jnccn.2013.0055","article-title":"Melanoma, version 2.2013: featured updates to the NCCN guidelines","volume":"11","author":"Coit","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1517\/14656566.2013.770475","article-title":"Trametinib (GSK1120212) in the treatment of melanoma","volume":"14","author":"Salama","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"R25-20230922","first-page":"21","article-title":"Dabrafenib for treatment of BRAF-mutant melanoma","volume":"7","author":"Kainthla","year":"2014","journal-title":"Pharmgenomics Pers Med"},{"key":"R26-20230922","first-page":"243","article-title":"Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma","volume":"4","author":"Fisher","year":"2012","journal-title":"Cancer Manag Res"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrclinonc.2011.69","article-title":"BRAF targeted therapy changes the treatment paradigm in melanoma","volume":"8","author":"Ribas","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/PPO.0000000000000024","article-title":"A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States","volume":"20","author":"Flaherty","year":"2014","journal-title":"Cancer J"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/cncr.30663","article-title":"A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: a trial of the ECOG-ACRIN Cancer Research Group (E2607)","volume":"123","author":"Kalinsky","year":"2017","journal-title":"Cancer"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J Clin Oncol"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/ng.3382","article-title":"Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway","volume":"47","author":"Shain","year":"2015","journal-title":"Nat Genet"},{"key":"R37-20230922","first-page":"241","article-title":"A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance","volume":"71","author":"Dietel","year":"2011","journal-title":"Lung Cancer"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.lungcan.2010.11.014","article-title":"EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations","volume":"71","author":"Tiseo","year":"2011","journal-title":"Lung Cancer"},{"key":"R39-20230922","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1535-7163.MCT-12-0530","article-title":"Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine","volume":"11","author":"Wilmott","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"R40-20230922","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrclinonc.2015.175","article-title":"The influence of subclonal resistance mutations on targeted cancer therapy","volume":"13","author":"Schmitt","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"R41-20230922","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/PAS.0000000000000911","article-title":"Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions","volume":"41","author":"Hechtman","year":"2017","journal-title":"Am J Surg Path"},{"key":"R42-20230922","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3835(01)00530-4","article-title":"Trk receptor tyrosine kinases: a bridge between cancer and neural development","volume":"169","author":"Nakagawara","year":"2001","journal-title":"Cancer Lett"},{"key":"R43-20230922","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0888-7543(95)80226-C","article-title":"Rapid physical mapping of the human trk protooncogene (NTRK1) to human chromosome 1q21-q22 by P1 clone selection, fluorescence in situ hybridization (FISH), and computer-assisted microscopy","volume":"26","author":"Weier","year":"1995","journal-title":"Genomics"},{"key":"R44-20230922","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cncr.29887","article-title":"NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States","volume":"122","author":"Prasad","year":"2016","journal-title":"Cancer"},{"key":"R45-20230922","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/pbc.26433","article-title":"Identification of NTRK fusions in pediatric mesenchymal tumors","volume":"64","author":"Pavlick","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R46-20230922","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1038\/onc.2014.406","article-title":"The landscape and therapeutic relevance of cancer-associated transcript fusions","volume":"34","author":"Yoshihara","year":"2015","journal-title":"Oncogene"},{"key":"R47-20230922","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1126\/science.1065874","article-title":"Identification of ubiquitin ligases required for skeletal muscle atrophy","volume":"294","author":"Bodine","year":"2001","journal-title":"Science"},{"key":"R48-20230922","first-page":"5","article-title":"Transcriptional activator TAp63 is upregulated in muscular atrophy during ALS and induces the pro-atrophic ubiquitin ligase Trim63","volume":"26","author":"von Grabowiecki","year":"2016","journal-title":"Elife"},{"key":"R49-20230922","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.celrep.2015.09.037","article-title":"New functional signatures for understanding melanoma biology from tumor cell lineage-specific analysis","volume":"13","author":"Rambow","year":"2015","journal-title":"Cell Rep"},{"key":"R50-20230922","doi-asserted-by":"crossref","first-page":"9660","DOI":"10.1074\/jbc.M114.609685","article-title":"Tumor necrosis factor (TNF) receptor-associated factor (TRAF)-interacting protein (TRIP) negatively regulates the TRAF2 ubiquitin-dependent pathway by suppressing the TRAF2-sphingosine 1-phosphate (S1P) interaction","volume":"290","author":"Park","year":"2015","journal-title":"J Biol Chem"},{"key":"R51-20230922","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1038\/cdd.2015.35","article-title":"TRAF2 is a biologically important necroptosis suppressor","volume":"22","author":"Petersen","year":"2015","journal-title":"Cell Death Differ"},{"key":"R52-20230922","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/onc.2013.543","article-title":"TRAF2 is an NF-kappaB-activating oncogene in epithelial cancers","volume":"34","author":"Shen","year":"2015","journal-title":"Oncogene"},{"key":"R53-20230922","doi-asserted-by":"crossref","first-page":"612","DOI":"10.4161\/cbt.28181","article-title":"Overexpression of DDR2 contributes to cell invasion and migration in head and neck squamous cell carcinoma","volume":"15","author":"Xu","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"R54-20230922","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1158\/0008-5472.CAN-16-1099","article-title":"GON4L drives cancer growth through a YY1-androgen receptor-CD24 axis","volume":"76","author":"Agarwal","year":"2016","journal-title":"Cancer Res"},{"key":"R55-20230922","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1084\/jem.20100147","article-title":"The Justy mutation identifies Gon4-like as a gene that is essential for B lymphopoiesis","volume":"207","author":"Lu","year":"2010","journal-title":"J Exp Med"},{"key":"R56-20230922","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdw042","article-title":"What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann Oncol"},{"key":"R57-20230922","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2159-8290.CD-15-0940","article-title":"Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov"},{"key":"R58-20230922","article-title":"Neurotrophin Trk receptors: new targets for cancer therapy","author":"Meldolesi","journal-title":"Physiol Biochem Pharmacol"},{"key":"R59-20230922","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with trk fusion-positive solid tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"R60-20230922","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA2501","article-title":"The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers","author":"Hyman","year":"2017","journal-title":"J Clin Oncol"},{"key":"R61-20230922","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201808000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:28:35Z","timestamp":1695421715000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201808000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001070","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}